Literature DB >> 27060607

Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013.

F Khan1, C Maradey-Romero1, S Ganocy2, R Frazier1, R Fass1.   

Abstract

BACKGROUND: Surgical fundoplication has been considered to be one of the leading therapeutic modalities for gastro-oesophageal reflux disease (GERD) during the last several decades. AIM: To determine the trend of surgical fundoplication utilisation in GERD patients during the last decade in the United States.
METHODS: Population-based study using a large nationwide database, the Explorys database system, to identify patients diagnosed with GERD and those who underwent surgical fundoplication. Using a quadratic regression model, we determined and compared the trends of surgical fundoplication utilisation annually from 2004 to 2013.
RESULTS: We identified 4 059 060 patients with the diagnosis of GERD, of whom 2343 (0.05%) underwent surgical fundoplication between 2004 and 2013. There was a significant decline in the number of surgical fundoplications performed over the last 5 years from 0.062% in 2009 to 0.047% in 2013 (P < 0.05). Female patients accounted for the majority of those who underwent fundoplication (62.52%). Caucasian patients between the ages of 18 and 65 years were the most likely group to undergo surgical fundoplication (66.28%). The number of overweight patients undergoing surgical fundoplication has been significantly increasing over the last decade (P < 0.05). Importantly, 80% of surgical patients were treated with a proton pump inhibitor (PPI) post surgical fundoplication by 2013 (P < 0.001).
CONCLUSIONS: Utilisation of surgical fundoplication in GERD patients has been steadily declining over the past 5 years. The vast majority of patients will resume PPI treatment after surgical fundoplication.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27060607     DOI: 10.1111/apt.13611

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  A budget impact analysis of a magnetic sphincter augmentation device for the treatment of medication-refractory mechanical gastroesophageal reflux disease: a United States payer perspective.

Authors:  John Pandolfino; John Lipham; Amarpreet Chawla; Nicole Ferko; Andrew Hogan; Rana A Qadeer
Journal:  Surg Endosc       Date:  2019-09-26       Impact factor: 4.584

Review 2.  Magnetic sphincter augmentation for gastroesophageal reflux disease: review of clinical studies.

Authors:  Emanuele Asti; Alberto Aiolfi; Veronica Lazzari; Andrea Sironi; Matteo Porta; Luigi Bonavina
Journal:  Updates Surg       Date:  2018-07-18

3.  Surgery for benign esophageal disorders in the US: risk factors for complications and trends of morbidity.

Authors:  Francisco Schlottmann; Paula D Strassle; Marco G Patti
Journal:  Surg Endosc       Date:  2018-02-12       Impact factor: 4.584

4.  Endoscopic Approaches for the Treatment of Gastroesophageal Reflux Disease.

Authors:  Ronnie Fass
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-10

5.  Ineffective Esophageal Motility in Patients with GERD is no Contraindication for Nissen Fundoplication.

Authors:  Milena Nikolic; Katrin Schwameis; Ivan Kristo; Matthias Paireder; Aleksa Matic; Georg Semmler; Lorenz Semmler; Sebastian F Schoppmann
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

6.  Antireflux Surgery in the USA: Influence of Surgical Volume on Perioperative Outcomes and Costs-Time for Centralization?

Authors:  Francisco Schlottmann; Paula D Strassle; Marco G Patti
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

Review 7.  Surgical Treatment of Gastroesophageal Reflux Disease.

Authors:  Francisco Schlottmann; Fernando A Herbella; Marco E Allaix; Fabrizio Rebecchi; Marco G Patti
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

8.  Practice-Changing Milestones in Anti-reflux and Hiatal Hernia Surgery: a Single Surgeon Perspective over 27 years and 1200 Operations.

Authors:  Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2021-02-02       Impact factor: 3.452

Review 9.  Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.

Authors:  Fahmi Shibli; Yoshitaka Kitayama; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2020-03-17

10.  Antireflux Surgery and Barrett's Esophagus: Myth or Reality?

Authors:  Fernando A M Herbella; Francisco Schlottmann; Marco G Patti
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.